New CVIM set to improve global animal health

Buffalos in the wild; one of them is staring right at the camera

A new centre at The Pirbright Institute will accelerate the development of animal vaccines to combat emerging and urgent infectious diseases.

The new Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM), based at The Pirbright Institute, will be created through a joint initiative between:

The centre is designed to accelerate the development of animal vaccines to combat emerging and urgent infectious diseases.

Catastrophic consequences

The consequences of livestock disease can be catastrophic. As well as posing a very real risk to global food security and international trade, livestock disease also presents a significant threat to global human health due to its pandemic potential.

The UK remains a world-leader in the early-stage development of vaccines for both human and veterinary medicine. Globally, however, we need to strengthen our collective capacity to translate scientific discoveries into solutions for the most challenging veterinary infectious diseases.

The new CVIM will bridge the gaps between research and expertise in process development and manufacturing.

Although scientifically independent, the location of the new centre at The Pirbright Institute means it will be able to leverage the significant previous investments into:

  • Pirbright’s high containment facilities for laboratory and animal studies
  • expertise in veterinary virology, immunology and vaccine development

A ‘one health’ approach

The collaborative investment, totalling almost £40 million, promotes a ‘one health’ approach towards improving the health and wellbeing of animals and humans on a global scale.

And as well as strengthening the UK’s own emergency response capacity and capability, it will bring about tangible health and economic benefits by focusing on diseases prevalent in low and middle-income countries.

CVIM will achieve this by:

  • establishing a vital component of the global pandemic preparedness programme with emergency response vaccine development and production capacity for orphan livestock and zoonotic diseases of high consequence and newly emerging zoonotic viral diseases, thus limiting their spread and impact on both livestock and humans
  • addressing niche markets where there is an important clinical need for new vaccines but where it is commercially challenging
  • bridging the gaps between research and downstream commercial development of vaccines by supporting manufacturing innovation to reduce costs, scale production and support the adoption of novel platform technologies, thereby accelerating the development of animal and human vaccines
  • establishing the utility of novel vaccine platform technologies for neglected livestock diseases and urgent emerging zoonotic diseases that currently have insufficient commercial drive to justify industry investment
  • enhancing CVIM’s reputation as a leading international pilot-scale manufacturing centre that is able to attract, train and retain world class scientific, manufacturing and regulatory expertise and share its expertise for maximum global impact

Meeting a global need

Professor Bryan Charleston, Director of The Pirbright Institute, said:

There is a global unmet need to develop vaccines for livestock keepers to control disease in their animals. Preventing disease by vaccination will help secure food supplies and so improve human health and welfare. The new centre based at The Pirbright Institute will develop production processes for novel vaccines to accelerate commercial development.

Supporting developing countries

Professor Charlotte Watts, Chief Scientific Adviser at FCDO, said:

New vaccines play a vital role in protecting the poorest and most vulnerable farmers in developing countries from the risks they face from animal disease. And as we’ve seen in the last decade, diseases that originate in animals, like COVID-19, can quickly spread, posing a threat to all of us. That’s why FCDO is proud to support the new centre for Veterinary Vaccine Innovation and Manufacturing with our partners at BBSRC and the Bill & Melinda Gates Foundation.

The new centre will harness the best of UK science and innovation, and working with partners in Africa and Asia, fast-track the development of vital new livestock vaccines.

Collaboration key to success

Professor Melanie Welham, Executive Chair of BBSRC, said:

The UK has a long track record of national and international excellence and leadership in infectious disease research and innovation. And collaboration is key if we are to deliver a real step change in our ability to effectively tackle infectious disease. This latest investment with our partners at FCDO and the Bill & Melinda Gates Foundation demonstrates the true value of our international partnerships in addressing major challenges that have the potential to impact our global society.

Advancing vaccine science

Samuel Thevasagayam, Director of Livestock at the Bill & Melinda Gates Foundation, said:

It’s difficult if not impossible to address high rates of poverty and malnutrition in Africa and South Asia without a significant focus on the several hundred million people – many of them women – who depend on livestock for income and proper nutrition. We always have viewed livestock vaccines as a powerful tool for supporting their needs, and promoting global health, which is why we’re excited to be part of a new effort to harness advances in vaccine science to confront zoonotic and neglected livestock diseases.

Top image:  Credit: CarlaMc, iStock, Getty Images Plus via Getty Images

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.